Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390

We read with great interest the article by Bezin et  al. (1). Glucagon-like peptide 1 receptor agonist (GLP-1 RA) exposure in rodents is associated with thyroid C-cell hyperplasia, tumor formation, and calcitonin secretion. Using the French national health care insurance database, the authors conducted a nested case-control analysis to determine the risk of thyroid neoplasm among individuals with type 2 diabetes treated with a GLP-1 RA. A total of 2,562 case subjects with thyroid cancer and 45,184 control subjects were included. The use of GLP-1 RA for 1 –3 years was associated with an increased risk of thyroid cancer with adjusted hazard ratio (HR) 1.58 and medullary cancer with HR 1.78 after adjustment for various confounders.
Source: Diabetes Care - Category: Endocrinology Source Type: research